Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 275 M
EBIT 2016 -101 M
Net income 2016 -130 M
Finance 2016 40,6 M
Yield 2016 -
Sales 2017 329 M
EBIT 2017 -98,0 M
Net income 2017 -132 M
Finance 2017 119 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 18,8x
EV / Sales2017 15,5x
Capitalization 5 212 M
More Financials
Company
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of antisense drug discovery.It operates its business through the Ionis Core and Akea Therapeutics segments.The Ionis Core segment involves a a novel drug discovery platform generate a broad pipeline of drugs.The Akea... 
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ISIS PHARMACEUTICALS, INC.
12/01 OTONOMY : Appoints Kathie M. Bishop, Ph.D., as Chief Scientific Officer
11/17 IONIS PHARMACEUTICALS : Reports Financial Results and Highlights for Third Quart..
11/17 IONIS PHARMACEUTICALS : 1,000 Shares of Stock are Sold by Ionis Pharmaceuticals ..
11/15 ISIS PHARMACEUTICALS : Ionis Pharmaceuticals Reports Positive Clinical Data from..
11/10 IONIS PHARMACEUTICALS : Reports Positive Phase 2 Data for IONIS-FXI Rx in Patien..
11/09 IONIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
11/09 IONIS PHARMACEUTICALS, INC. (NASDAQ : IONS) Files An 8-K Reports Financial Resul..
11/09 IONIS PHARMACEUTICALS INC : Results of Operations and Financial Condition, Finan..
11/09 IONIS PHARMACEUTICALS : misses Street 3Q forecasts
11/08 IONIS PHARMACEUTICALS INC. : (IONS) is Trading Lower on Unusual Volume for Novem..
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
2014A resistance as obstacle
More Strategies
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Advertisement
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 13
Average target price 43,6 $
Spread / Average Target 1,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Director
Elizabeth L. Hougen Chief Financial Officer & Senior VP-Finance
Joseph H. Wender Independent Director
Frederick T. Muto Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, ..-6.12%5 212
INCYTE CORPORATION-7.86%19 219
QUINTILES IMS HOLDINGS..6.32%18 225
CELLTRION, INC.--.--%9 953
SEATTLE GENETICS, INC.48.64%9 442
LONZA GROUP AG11.34%9 247
More Results